Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.
| Drug | Target | Relationship | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | Reposition | #cancers |
|---|---|---|---|---|---|---|---|---|---|---|---|
| nabiximols, temozolomide, nabiximols-matched placebo | CYP3A7 | Direct | 1 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | SMO | SSL via SMO | 3 | ||||||||
| pazopanib | SH2B3 | SSL via SH2B3 | 2 | ||||||||
| pembrolizumab, sonidegib | SMO | SSL via SMO | 2 | ||||||||
| alisertib | AURKA | SSL via AURKA | 1 | ||||||||
| alisertib, gemcitabine | AURKA | SSL via AURKA | 1 | ||||||||
| apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib | SMO | SSL via SMO | 1 | ||||||||
| biopsy, biospecimen collection, ceralasertib, computed tomography, echocardiography, multigated acquisition scan, positron emission tomography, trastuzumab deruxtecan | ATR | SSL via ATR | 1 | ||||||||
| biopsy, biospecimen collection, echocardiography, radionuclide imaging, vismodegib | SMO | SSL via SMO | 1 | ||||||||
| bosutinib | CAMK2G | SSL via CAMK2G | 1 | ||||||||
| ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin | TP53 | SSL via TP53 | 1 | ||||||||
| ceralasertib, olaparib, durvalumab | ATR | SSL via ATR | 1 | ||||||||
| cisplatin, carboplatin, etoposide, durvalumab, ceralasertib | ATR | SSL via ATR | 1 | ||||||||
| diagnostic laboratory biomarker analysis, erlotinib hydrochloride, gemcitabine hydrochloride, vismodegib | SMO | SSL via SMO | 1 | ||||||||
| dimethyl fumarate, temozolomide, radiation therapy | KEAP1 | SSL via KEAP1 | 1 | ||||||||
| disulfiram, copper, alkylating agents | GAPDH | SSL via GAPDH | 1 | ||||||||
| disulfiram, copper, alkylating agents | SRSF1 | SSL via SRSF1 | 1 | ||||||||
| enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) | AURKA | SSL via AURKA | 1 | ||||||||
| enzastaurin, lomustine | AURKA | SSL via AURKA | 1 | ||||||||
| enzastaurin, temozolomide, radiation therapy | AURKA | SSL via AURKA | 1 | ||||||||
| gemcitabine hydrochloride, hydrocortisone/placebo, vismodegib | SMO | SSL via SMO | 1 | ||||||||
| gemcitabine, ribociclib, sonidegib, trametinib, filgrastim | SMO | SSL via SMO | 1 | ||||||||
| hyperfractionated radiation therapy, stereotactic radiosurgery, alisertib, quality-of-life assessment | AURKA | SSL via AURKA | 1 | ||||||||
| motixafortide, cemiplimab, gemcitabine, nab paclitaxel | CXCR4 | SSL via CXCR4 | 1 | ||||||||
| pantoprazole, omeprazole | DDAH1 | SSL via DDAH1 | 1 | ||||||||
| pazopanib, 5-fu, oxaliplatin, leukovorin (flo) | SH2B3 | SSL via SH2B3 | 1 | ||||||||
| pazopanib, lapatinib | SH2B3 | SSL via SH2B3 | 1 | ||||||||
| pazopanib, placebo | SH2B3 | SSL via SH2B3 | 1 | ||||||||
| pegilodecakin, paclitaxel or docetaxel and carboplatin or cisplatin, folfox (oxaliplatin/leucovorin/5-fluorouracil), gemcitabine/nab-paclitaxel, capecitabine, pazopanib, pembrolizumab, paclitaxel, nivolumab, gemcitabine/carboplatin | SH2B3 | SSL via SH2B3 | 1 | ||||||||
| plerixafor | CXCR4 | SSL via CXCR4 | yes | 1 | |||||||
| plerixafor, temozolomide, whole-brain radiotherapy (wbrt), radiation therapy | CXCR4 | SSL via CXCR4 | 1 | ||||||||
| radiation therapy, temozolomide, plerixafor, laboratory biomarker analysis, pharmacological study | CXCR4 | SSL via CXCR4 | 1 | ||||||||
| topotecan, pazopanib | SH2B3 | SSL via SH2B3 | 1 | ||||||||
| vismodegib, sirolimus, positron emission tomography, computed tomography, pharmacological study, laboratory biomarker analysis, fludeoxyglucose f 18 | SMO | SSL via SMO | 1 | ||||||||
| vismodegib, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study | SMO | SSL via SMO | 1 | ||||||||
| amifampridine | KCNQ4 | SSL via KCNQ4 | yes | 0 | |||||||
| amifampridine phosphate | KCNQ4 | SSL via KCNQ4 | yes | 0 | |||||||
| clofarabine | POLD1 | SSL via POLD1 | yes | 0 | |||||||
| dalfampridine | KCNQ4 | SSL via KCNQ4 | yes | 0 | |||||||
| dimethyl fumarate | KEAP1 | SSL via KEAP1 | yes | 0 | |||||||
| diroximel fumarate | KEAP1 | SSL via KEAP1 | yes | 0 | |||||||
| ezogabine | KCNQ4 | SSL via KCNQ4 | yes | 0 | |||||||
| fingolimod | S1PR2 | SSL via S1PR2 | yes | 0 | |||||||
| fingolimod hydrochloride | S1PR2 | SSL via S1PR2 | yes | 0 | |||||||
| gemcitabine | POLD1 | SSL via POLD1 | yes | 0 | |||||||
| gemcitabine hydrochloride | POLD1 | SSL via POLD1 | yes | 0 | |||||||
| glasdegib | SMO | SSL via SMO | yes | 0 | |||||||
| glasdegib maleate | SMO | SSL via SMO | yes | 0 | |||||||
| guanidine | KCNQ4 | SSL via KCNQ4 | yes | 0 | |||||||
| guanidine hydrochloride | KCNQ4 | SSL via KCNQ4 | yes | 0 | |||||||
| monomethyl fumarate | KEAP1 | SSL via KEAP1 | yes | 0 | |||||||
| pentoxifylline | PDE6H | SSL via PDE6H | yes | 0 | |||||||
| phenindione | GGCX | SSL via GGCX | yes | 0 | |||||||
| sonidegib | SMO | SSL via SMO | yes | 0 | |||||||
| sonidegib phosphate | SMO | SSL via SMO | yes | 0 | |||||||
| vismodegib | SMO | SSL via SMO | yes | 0 |